

A CONTROLLED CLINICAL STUDY WITH TAXADROL®

Guideline
FDA

Over Seeing Physician:
Dr. Beesen, ND
Blood Draw Facility:
Laboratory Corporation of America
Lab Director:
Dr. Kristin Mantiel, MD

Study completed on March 25th, 2009

Performing Laboratory

BioCeutical Research & Development Laboratory
Montana Division
2376 Main Street
Room 14
Billings, MT 59105

BRDL Study No.
J81508

Introduction:

The study was performed to assess the short-term benefits and possible side effects of Taxadrol® in human being. The study was intended to provide information on the potential health benefits and side effects of Taxadrol® for athletes or any males suffering from low testosterone levels. Data from this study may serve as a basis for classification and/or labeling of the test article. Data also will serve as validated marketing research that presents the case for the effectiveness of Taxadrol®. The study was performed by BioCeutical Research & Development Laboratory at 2376 Main Street, Room 14, Billings, Montana. The protocol was signed by the Study Director on December 1st, 2007. The study was initiated with several baseline test and then the introduction of test article on May 15th, 2008 and concluded on August 15th, 2008.

Procedure:

Two bodybuilders were chosen for the study with low testosterone. Subjects were screened to make sure testosterone levels were low, they were healthy, had not taken anabolic steroids for a period of at least 4 years, were over 40 years of age and were willing to go off all other supplements. Their workouts consisted of moderate training 5 days per week with cardio three days per week. No changes were made to their training schedule or diet.

Subject 1:

| | |
|------------------------------|-----------|
| Base Line Serum Testosterone | 187 ng/dl |
|------------------------------|-----------|

| | |
|--------------------|-----------|
| Serum Albumin | 4.2 g/dl |
| C-Reactive Protein | <0.8 mg/L |

Subject 2:

| | |
|------------------------------|-----------|
| Base Line Serum Testosterone | 225 ng/dl |
|------------------------------|-----------|

| | |
|--------------------|-----------|
| Serum Albumin | 4.0 g/dl |
| C-Reactive Protein | <0.7 mg/L |

Both subjects were administered Taxadrol® via oral administration

| | |
|-----------|--|
| Week 1: | 30 mg once per day in the A.M. |
| Week 2-4: | 30 mg x twice per day A.M., P.M. |
| Week 5-7: | 30 mg x three times per day A.M., M.D., P.M. |
| Week 8: | 30 mg once per day A.M. |

Results:

Subject 1:

| | |
|--------------------|------------|
| Serum Testosterone | 755 ng/ml |
| Serum Albumin | 4.1 g/dl |
| C-Reactive Protein | <0.07 mg/L |

Subject 2:

| | |
|--------------------|------------|
| Serum Testosterone | 400 ng/ml |
| Serum Albumin | 4.0 g/dl |
| C-Reactive Protein | <0.07 mg/L |

Summary:

Both subjects experienced dramatic increases in testosterone levels. Training improved with increases in intensity, increases in strength, increases in libido, increases in body weight and a noticeable decrease in body fat. No side effects reported but a slight increase in aggressiveness. Serum Albumin and C-Reactive Protein levels were good.

Conclusion:

Taxadrol® effectively raised testosterone levels in these two studies by an average of 180% with no side effects but increased in aggressiveness.